Personalis (NASDAQ:PSNL) Stock Rating Lowered by Wall Street Zen

Personalis (NASDAQ:PSNL) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

PSNL has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. BTIG Research boosted their price target on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Guggenheim boosted their price target on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Morgan Stanley dropped their price target on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating for the company in a research note on Thursday, March 5th. Finally, Needham & Company LLC boosted their price target on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Personalis presently has an average rating of “Moderate Buy” and an average target price of $11.50.

Personalis Stock Performance

Shares of PSNL stock opened at $5.98 on Friday. Personalis has a 1 year low of $3.84 and a 1 year high of $11.50. The firm’s 50 day moving average is $6.93 and its 200-day moving average is $8.23. The firm has a market capitalization of $626.23 million, a price-to-earnings ratio of -5.86 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The company had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.49 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. On average, equities research analysts forecast that Personalis will post -1.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Personalis

Large investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd increased its stake in Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after purchasing an additional 1,479 shares in the last quarter. International Assets Investment Management LLC bought a new stake in Personalis in the fourth quarter valued at approximately $31,000. Legal & General Group Plc bought a new stake in Personalis in the second quarter valued at approximately $30,000. BNP Paribas Financial Markets increased its stake in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares in the last quarter. Finally, Farther Finance Advisors LLC bought a new stake in Personalis in the third quarter valued at approximately $66,000. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.